GALE Share Price

Open 0.60 Change Price %
High 0.66 1 Day 0.02 3.23
Low 0.60 1 Week 0.07 12.28
Close 0.64 1 Month -0.10 -13.51
Volume 876887 1 Year -0.58 -47.54
52 Week High 4.75
52 Week Low 0.16
GALE Important Levels
Resistance 2 0.70
Resistance 1 0.67
Pivot 0.63
Support 1 0.61
Support 2 0.58
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
FTR 1.98 -1.98%
FTR 1.98 -1.98%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
More..
NASDAQ USA Top Gainers Stocks
AMCF 0.10 100.00%
LOCM 0.09 50.00%
SSH 2.31 32.76%
SSH 2.31 32.76%
SSH 2.31 32.76%
LTRE 2.40 31.87%
HPJ 4.90 30.67%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
ORIG 0.23 -68.49%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
VALV 0.02 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Galena Biopharma, Inc. (NASDAQ: GALE)

GALE Technical Analysis 5
As on 28th Mar 2017 GALE Share Price closed @ 0.64 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.15 & Strong Sell for SHORT-TERM with Stoploss of 1.06 we also expect STOCK to react on Following IMPORTANT LEVELS.
GALE Target for March
1st Target up-side 1.72
2nd Target up-side 2.4
3rd Target up-side 3.08
1st Target down-side -0.24
2nd Target down-side -0.92
3rd Target down-side -1.6
GALE Other Details
Segment EQ
Market Capital 139060160.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.galenabiopharma.com
GALE Address
GALE
4640 SW Macadam Avenue
Suite 270
Portland, OR 97239
United States
Phone: 855-855-4253
GALE Latest News
Interactive Technical Analysis Chart Galena Biopharma, Inc. ( GALE NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Galena Biopharma, Inc.
GALE Business Profile
Galena Biopharma, Inc. (Galena), formerly RXi Pharmaceuticals Corporation, incorporated on April 3, 2006, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics. The Company is pursuing the development of cancer therapeutics using peptide-based immunotherapy products, including its main product candidate, NeuVaxTM (E75), for the treatment of breast cancer and other tumors. NeuVax is a peptide-based immunotherapy intended to reduce the recurrence of breast cancer in low-to-intermediate HER2-positive breast cancer patients not eligible for trastuzumab (Herceptin; Genentech/Roche). In January 2014, Galena Biopharma Inc acquired Mills Pharmaceuticals, which has the worldwide rights to GALE-401 (Anagrelide CR), a patented, controlled release formulation of anagrelide.